SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

PRODUCT INFORMATION

Droloxifene

Item No. 33406

CAS Registry No.:	82413-20-5
Formal Name:	3-[(1E)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenyl-1-buten-1-yl]-phenol
Synonyms:	FK-435, 3-Hydroxytamoxifen, K-060-E
MF:	$C_{26}H_{29}NO_2$
FW:	387.5
Purity:	≥98%
Supplied as:	A crystalline solid
Storage:	-20°C
Stability:	≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Droloxifene is supplied as a crystalline solid. A stock solution may be made by dissolving the droloxifene in the solvent of choice, which should be purged with an inert gas. Droloxifene is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of droloxifene in these solvents is approximately 1, 15, and 30 mg/ml, respectively.

Droloxifene is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, droloxifene should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Droloxifene has a solubility of approximately 0.25 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Droloxifene is a non-steroidal selective estrogen receptor modulator (SERM) and derivative of tamoxifen (Item No. 13258).[1] Droloxifene binds to the estrogen receptor (ER) in rabbit uterine homogenates (IC_{50} = 24 nM in a radioligand binding assay) and inhibits expression of an estrogen-dependent luciferase reporter induced by 17β-estradiol (Item No. 10006315; IC_{50} = 49.8 nM).[2,3] It inhibits 17β-estradiol-stimulated growth of MCF-7, ZR-75-1, and T47D human breast cancer cells in a concentration-dependent manner.[4] Droloxifene (10 mg/kg) increases wet uterine weight in mice.[5]

References

1. Robertson, J.F.R. Selective oestrogen receptor modulators/new antioestrogens: A clinical perspective. *Cancer Treat. Rev.* **30(8)**, 695-706 (2004).
2. Löser, R., Seibel, K., Roos, W., *et al.* *In vivo* and *in vitro* antiestrogenic action of 3-hydroxytamoxifen, tamoxifen and 4-hydroxytamoxifen. *Eur. J. Cancer Clin. Oncol.* **21(8)**, 985-990 (1985).
3. Shen, E.S., Meade, E.H., Pérez, M.C., *et al.* Expression of functional estrogen receptors and galanin messenger ribonucleic acid in immortalized luteinizing hormone-releasing hormone neurons: Estrogenic control of galanin gene expression. *Endocrinology* **139(3)**, 939-948 (1998).
4. Kawamura, I., Mizota, T., Lacey, E., *et al.* The estrogenic and antiestrogenic activities of droloxifene in human breast cancers. *Jpn. J. Pharmacol.* **63(1)**, 27-34 (1993).
5. Greenberger, L.M., Annable, T., Collins, K.I., *et al.* A new antiestrogen, 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-piperidin-1-yl-ethoxy)-benzyl]-1H-indol-5-ol hydrochloride (ERA-923), inhibits the growth of tamoxifen-sensitive and -resistant tumors and is devoid of uterotropic effects in mice and rats. *Clin. Cancer Res.* **7(10)**, 3166-3177 (2001).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM